[1]
Ikeda-Matsuo, Y.; Miyata, H.; Mizoguchi, T.; Ohama, E.; Naito, Y.; Uematsu, S.; Akira, S.; Sasaki, Y.; Tanabe, M. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson’s disease. Neurobiol. Dis., 2019, 124, 81-92.
[2]
Miyanishi, K.; Choudhury, M.E.; Watanabe, M.; Kubo, M.; Nomoto, M.; Yano, H.; Tanaka, J. Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson’s disease model. Neurochem. Int., 2019, 122, 38-46.
[3]
Rocha, M.D.; Viegas, F.P.; Campos, H.C.; Nicastro, P.C.; Fossaluzza, P.C.; Fraga, C.A.; Barreiro, E.J.; Viegas, C., Jr The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer’s disease. CNS Neurol. Disord. Drug Targets, 2011, 10(2), 251-270.
[4]
Santos, V.L. Perfil epidemiológico da doença de Parkinson no Brasil, Centro universitário de Brasília., 2015.
[5]
Barbosa, A.F.; Voos, M.C.; Chen, J.; Francato, D.C.V.; Souza, C.O.; Barbosa, E.R.; Chien, H.F.; Mansur, L.L. Cognitive or cognitive-motor executive function tasks? Evaluating verbal fluency measures in people with parkinson’s disease. BioMed Res. Int., 2017, 2017, 1-7.
[6]
Tan, L.C.; Venketasubramanian, N.; Jamora, R.D.; Heng, D. Incidence of Parkinson’s disease in Singapore. Parkinsonism Relat. Disord., 2007, 13(1), 40-43.
[7]
Song, J.; Kim, J. Degeneration of dopaminergic neurons due to metabolic alterations and Parkinson’s Disease. Front. Aging Neurosci., 2016, 8(65), 1-11.
[8]
Caixeta, L.; Vieira, R.T. Demência na Doença de Parkinson. Rev. Bras. Psiquiatr., 2008, 30(4), 375-383.
[9]
Muangpaisan, W.; Hori, H.; Brayne, C. Systematic review of the prevalence and incidence of Parkinson’s Disease in Asia. J. Epidemiol., 2009, 19(6), 281-293.
[10]
Tan, L.C.S. Epidemiology of Parkinson’s disease. Neurol. Asia, 2013, 18(3), 231-238.
[11]
Lau, L.M.L.; Breteler, M.M.B. Epidemiology of Parkinson’s disease. Lancet Neurol., 2006, 5(6), 525-535.
[12]
Bellou, V.; Belbasis, L.; Tzoulaki, I.; Evangelou, E.; Ioannidis, J.P.A. Environmental risk factors and Parkinson’s disease: An umbrella review of meta-analyses. Parkinsonism Relat. Disord., 2016, 23, 1-9.
[13]
Onozawa, R.; Tsugawa, J.; Tsuboi, Y.; Fukae, J.; Mishima, T.; Fujioka, S. The impact of early morning off in Parkinson’s disease on patient quality of life and caregiver burden. J. Neurol. Sci., 2016, 364, 1-5.
[14]
Pereira, M.C.L.; Suzuki, D.E.; Janjoppi, L.; Okamoto, O.K. Strategies for neuronal recovery in experimental models of Parkinson’s disease. Einstein , 2007, 5(4), 387-391.
[15]
Abbas, M.M.; Xu, Z.; Tan, L.C.S. Epidemiology of Parkinson’s Disease-East Versus West. Mov. Disord. Clin. Pract. , 2017, 5(1), 14-28.
[16]
Dorsey, E.R.; Constantinescu, R.; Thompson, J.P.; Biglan, K.M.; Holloway, R.G.; Kieburtz, K.; Marshall, F.J.; Ravina, B.M.; Schifitto, G.; Siderowf, A.; Tanner, C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 2007, 68(5), 384-386.
[17]
Huot, P.; Sgambato-Faure, V.; Fox, S.H.; McCreary, A.C. Serotonergic approaches in Parkinson’s Disease: Translational perspectives, an update. ACS Chem. Neurosci., 2017, 8(5), 973-986.
[18]
Gallese, V.; Cuccio, V. The neural exploitation hypothesis and its implications for an embodied approach to language and cognition: Insights from the study of action verbs processing and motor disorders in Parkinson’s disease. Cortex, 2018, 100, 215-225.
[19]
Braak, H.; Del Tredici, K.; Rüb, U.; de Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging, 2003, 24(2), 197-211.
[20]
Wise, Jr, J.P.; Price, C.G.; Amaro, J.A.; Cannon, J.R. Autophagy disruptions associated with altered optineurin expression in extranigral regions in a rotenone model of Parkinson’s Disease. Front. Neurosci., 2018, 12, 289.
[21]
Silva, P.G.C.; Domingues, D.D.; Carvalho, L.A.; Allodi, S.; Correa, C.L. Neurotrophic factors in Parkinson’s disease are regulated by exercise: Evidence-based pactice. J. Neurol. Sci., 2016, 363, 5-15.
[22]
Youdim, M.B.H. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. J. Neural Transm. (Vienna), 2018, 125(11), 1719-1733.
[23]
Broski, S.M.; Hunt, C.H.; Johnson, G.B.; Morreale, R.F.; Lowe, V.J.; Peller, P.J. Structural and functional imaging in parkinsonian syndromes. Radiographics, 2014, 34(5), 1273-1292.
[24]
Choudhry, H.; Perlmuter, L.C. Non CNS pathogenic origin of Parkinson’s disease. J. Neurol., 2017, 264(9), 2027-2030.
[25]
Mori, I. Viremic attack explains the dual-hit theory of Parkinson’s disease. Med. Hypotheses, 2017, 101, 33-36.
[26]
Braak, H.; Braak, E. Pathoanatomy of Parkinson’s disease. J. Neurol., 2000, 247(Suppl. 2), II3-II10.
[27]
Butt, A.H.; Rovini, E.; Dolciotti, C.; De Petris, G.; Bongioanni, P.; Carboncini, M.C.; Cavallo, F. Objective and automatic classification of Parkinson disease with Leap Motion controller. Biomed. Eng. Online, 2018, 17(168), 1-21.
[28]
Mironova, Y.S.; Zhukova, I.A.; Zhukova, N.G.; Alifirova, V.M.; Izhboldina, O.P.; Latypova, A.V. Parkinson's disease and glutamate excitotoxicity. Zh Nevrol. Psikhiatr. Im. S S Korsakova, , 2018, 118(6. Vyp. 2), 50-54.
[29]
Caggiu, E.; Arru, G.; Hosseini, S.; Niegowska, M.; Sechi, G.; Zarbo, I.R.; Sechi, L.A. Inflammation, Infectious Triggers, and Parkinson’s Disease. Front. Neurol., 2019, 10(122), 1-9.
[30]
Kalia, L.V.; Lang, A.E. Parkinson’s disease. Lancet, 2015, 386(9996), 896-912.
[31]
McKinley, E.T.; Baranowski, T.C.; Blavo, D.O.; Cato, C.; Doan, T.N.; Rubinstein, A.L. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons. Brain Res. Mol. Brain Res., 2005, 141(2), 128-137.
[32]
Kaur, R.; Mehan, S.; Singh, S. Understanding multifactorial architecture of Parkinson’s disease: Pathophysiology to management. Neurol. Sci., 2019, 40(1), 13-23.
[33]
Braun, G.H.; Jorge, D.M.M.; Ramos, H.P.; Alves, R.M.; da Silva, V.B.; Giuliatti, S.; Sampaio, S.V.; Taft, C.A.; Silva, C.H.T.P. Molecular dynamics, flexible docking, virtual screening, ADMET predictions, and molecular interaction field studies to design novel potential MAO-B inhibitors. J. Biomol. Struct. Dyn., 2008, 25(4), 347-355.
[34]
Souza, L.R.; Picanço, R.M.; Pinheiro, A.A.; Silva, K.R.; Taft, C.A.; da Silva, C.H.T. de P.; Santos, C.B.; Hage-Melim, L.I.S. Development of Monoamine Oxidase B inhibitors with Antiparkinson activity. Curr. Phys. Chem., 2016, 6, 40-52.
[35]
Cacabelos, R. Parkinson’s disease: From pathogenesis to pharmacogenomics. Int. J. Mol. Sci., 2017, 18(3), 551.
[36]
Liu, C.; Liang, M.C.; Soong, T.W. Nitric Oxide, Iron and Neurodegeneration. Front. Neurosci., 2019, 13(114), 1-10.
[37]
Redenšek, S.; Trošt, M.; Dolžan, V. Genetic determinants of Parkinson’s Disease: Can they help to stratify the patients based on the underlying molecular defect? Front. Aging Neurosci., 2017, 9(20), 1-17.
[38]
Picillo, M.; Lizarraga, K.J.; Friesen, E.L.; Chau, H.; Zhang, M.; Sato, C.; Rooke, G.; Munhoz, R.P.; Rogaeva, E.; Fraser, P.E.; Kalia, S.K.; Kalia, L.V. Parkinsonism due to A53E α-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. Mov. Disord., 2018, 33(12), 1950-1955.
[39]
Redenšek, S.; Flisar, D.; Kojovic, M.; Kramberger, M.G.; Georgiev, D.; Pirtošek, Z.; Trošt, M.; Dolžan, V. Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson’s disease. Front. Pharmacol., 2019, 10(8), 1-10.
[40]
Gan-Or, Z.; Liong, C.; Alcalay, R.N. GBA-Associated Parkinson’s disease and other synucleinopathies. Curr. Neurol. Neurosci., 2018, 18(8), 44.
[41]
Nussbaum, R.L.; Ellis, C.E. Alzheimer’s disease and Parkinson’s disease. N. Engl. J. Med., 2003, 348, 1356-1364.
[42]
Periquet, M.; Fulga, T.; Myllykangas, L.; Schlossmacher, M.G.; Feany, M. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J. Neurosci., 2007, 27(12), 3338-3346.
[43]
Surmeier, D.J.; Obeso, J.A.; Halliday, G.M. Parkinson’s disease is not simply a prion disorder. J. Neurosci., 2017, 37(41), 9799-9807.
[44]
Drotár, P.; Mekyska, J.R.; Rektorová, I.; Masarová, L.; Smékal, Z.; Faundez-Zanuy, M. Evaluation of handwriting kinematics and pressure for differential diagnosis of Parkinson’s disease. Artif. Intell. Med., 2016, 67, 39-46.
[45]
Wei, Z.; Li, X.; Li, X.; Liu, Q.; Cheng, Y. Oxidative stress in Parkinson’s disease: A systematic review and meta-analysis. Front. Mol. Neurosci., 2018, 11(236), 1-7.
[46]
Costa, M.F.B.N.A.; Reisdorfer, E.; Kempfer, S.S.; Porporatti, A.L.; Canto, G.L. Validade diagnóstica de biomarcadores na doença de Parkinson: Revisão sistemática e meta-análise. Ver. Bras. Enferm, 2018, 71(6), 3250-3259.
[47]
Parnetti, L.; Chiasserini, D.; Persichetti, E.; Eusebi, P.; Varghese, S.; Qureshi, M.M.; Dardis, A.; Deganuto, M.; De Carlo, C.; Castrioto, A.; Balducci, C.; Paciotti, S.; Tambasco, N.; Bembi, B.; Bonanni, L.; Onofrj, M.; Rossi, A.; Beccari, T.; El-Agnaf, O.; Calabresi, P. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease. Mov. Disord., 2014, 29(8), 1019-1027.
[48]
Kuhbach, K.; Hülsemann, M.; Herrmann, Y.; Kravchenko, K.; Kulawik, A.; Linnartz, C.; Peters, L.; Wang, K.; Willbold, J.; Willbold, D.; Bannach, O. Application of an amyloid beta oligomer standard in the sFIDA assay. Front. Neurosci., 2016, 10(8), 1-6.
[49]
Gibb, W.R.G.; Lees, A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 1988, 51(6), 745-752.
[50]
Argaud, S.; Verin, M.; Sauleau, P.; Grandjean, D. Facial Emotion Recognition in Parkinson’s disease: A review and new hypotheses. Mov. Disord., 2018, 33(4), 554-567.
[51]
Postuma, R.B.; Berg, D.; Stern, M.; Poewe, W.; Olanow, C.W.; Oertel, W.; Obeso, J.; Marek, K.; Litvan, I.; Lang, A.E.; Halliday, G.; Goetz, C.G.; Gasser, T.; Dubois, B.; Chan, P.; Bloem, B.R.; Adler, C.H.; Deuschl, G. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord., 2015, 30(12), 1591-1601.
[52]
Hustad, E.; Skogholt, A.H.; Hveem, K.; Aasly, J.O. The accuracy of the clinical diagnosis of Parkinson disease. The HUNT study. J. Neurol., 2018, 265(9), 2120-2124.
[53]
Basorttini, O.G.P.; Felício, A.C.; Aquino, C.C.H.A.; Pedroso, J.L. Progressive supranuclear palsy: New concepts. Arq. Neuropsiquiatr., 2010, 68(6), 938-946.
[54]
Glaab, E. Computational systems biology approaches for Parkinson’s disease. Cell Tissue Res., 2018, 373(1), 91-109.
[55]
Oliveira1, R.V.; Pereira, J.S. O papel da difusão por ressonância magnética na doença de Parkinson e no diagnóstico diferencial com parkinsonismo atípico. Radiol. Bras., 2017, 50(4), 250-257.
[56]
Modrego, P.J.; Fayed, N.; Artal, J. Correlation of findings in advanced MRI techniques with global severity scales in patients with Parkinson disease. Acad. Radiol., 2011, 18(2), 235-241.
[57]
Zaaroor, M.; Sinai, A.; Goldsher, D.; Eran, A.; Nassar, M.; Schelensiger, I. Magnetic resonance-guided focused ultrasound thalamotomy for tremor: A report of 30 Parkinson’s disease and essential tremor cases. J. Neurosurg., 2018, 128(1), 202-210.
[58]
Felicio, A.C.; Shih, M.C.; Cordeiro-Junior, C.; Andrade, L.A.F. Molecular imaging studies in Parkinson’s disease: Reducing diagnostic uncertainty. Neurologist, 2009, 15(1), 6-16.
[59]
Pavese, N.; Brooks, D.J. Imaging neurodegeneration in Parkinson’s disease. Biochim. Biophys. Acta, 2009, 1792(7), 722-729.
[60]
Foulds, P.; Mann, D.M.A.; Mitchell, J.D.; Allsop, D. Parkinson disease: Progress toward a molecular biomarker for Parkinson disease. Nat. Rev. Neurol., 2010, 6(7), 359-361.
[61]
Leggio, L.; Vivarelli, S.; L’Episcopo, L.; Tirolo, C.; Caniglia, S.; Testa, N.; Marchetti, B.; Iraci, N. microRNAs in Parkinson’s disease: From pathogenesis to novel diagnostic and therapeutic approaches. Int. J. Mol. Sci., 2017, 18(12), 2698.
[62]
Crispo, J.A.G.; Fortin, Y.; Thibault, D.P.; Emons, M.; Bjerre, L.M.; Kohen, D.E.; Perez-Lloret, S.; Mattison, D.; Willis, A.W.; Krewski, D.L. Trends in inpatient antiparkinson drug use in the USA, 2001-2012. Eur. J. Clin. Pharmacol., 2015, 71(8), 1011-1019.
[63]
Francardo, V.; Bez, F.; Wieloch, T.; Nissbrandt, H.; Ruscher, K.; Cenci, M.A. Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain, 2014, 137(Pt 7), 1998-2014.
[64]
Poewe, W.; Antonini, A. Novel formulations and modes of delivery of levodopa. Mov. Disord., 2015, 30(1), 114-120.
[65]
Rieck, M.; Schumacher-Schuh, A.F.; Atmann, V.; Callegari-Jacques, S.M.; Rieder, C.R.M.; Hutz, M.H. Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson’s disease. Pharmacogenomics J., 2018, 18(1), 196-200.
[66]
Müller, T.; Möhr, J.D. Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson disease. Expert Opin. Pharmacother., 2018, 19(18), 2063-2071.
[67]
Safe, S. Carbidopa: A selective Ah receptor modulator (SAhRM). Biochem. J., 2017, 474(22), 3763-3765.
[68]
Antonini, A.; Moro, E.; Godeiro, C.; Reichmann, H. Medical and surgical management of advanced Parkinson’s disease. Mov. Disord., 2018, 33(6), 900-908.
[69]
Shin, M.S.; Meong, H.Y.; An, D.I.; Lee, H.Y.; Sung, I.H. Treadmill exercise facilitates synaptic plasticity on dopaminergic neurons and fibers in the mouse model with Parkinson’s disease. Neurosci. Lett., 2016, 621, 28-33.
[70]
Kühn, J.; Haumesser, J.K.; Beck, M.H.; Altschüler, J.; Kühn, A.A.; Nikulin, V.V.; Riesen, C. Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico-basal ganglia loop circuit in vivo in experimental parkinsonism. Exp. Neurol.,, 2017, 298(Pt A), 122-133.
[71]
Reichmann, H. Modern treatment in Parkinson’s disease, a personal approach. J. Neural Transm. (Vienna), 2016, 123(1), 73-80.
[72]
Pastor, P.; Tolosa, E. Cabergoline in the treatment of Parkinson’s disease. Neurologia, 2003, 18(4), 202-209.
[73]
Gopinathan, G.; Horowski, R.; Suchy, I.H. Lisuride pharmacology and treatment of Parkinson’s disease. In Calne DB (Ed.) Drugs for the treatment of Parkinson’s disease, Handbook of Experimental Pharmacology,. , 1989; 88, pp. 471-513.
[74]
Italiano, D.; Bianchini, E.; Ilardi, M.; Cilia, R.; Pezzoli, G.; Zanettini, R.; Vacca, L.; Stocchi, F.; Bramanti, P.; Ciurleo, R.; Di Lorenzo, G.; Polimeni, G.; de Luise, C.; Ross, D.; Rijnbeek, P.; Sturkenboom, M.; Trifirò, G. Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. J. Neural Transm. (Vienna), 2015, 122(6), 799-808.
[75]
Pondal, M.; Teodoro, D.S.; Bermejo, F. Anticholinergic therapy and dementia in patients with Parkinson’s disease. J. Neurol., 1996, 243(7), 543-545.
[76]
Porter, M.C.; Apprah-Kubf, L.S.; Chaudhuri, K.R. Treatment of Parkinson’s disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist. Int. J. Clin. Pract., 2002, 56(6), 468-474.
[77]
Faddoul, L.; Chahine, B.; Haydar, S.; Abourida, S.; Hallit, S.; Raad, E. The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients. Pharm. Pract. (Granada), 2018, 16(4), 1220.
[78]
Pardeshi, C.V.; Belgamwar, V.S. Ropinirole-dextran sulfate nanoplex for nasal administration against Parkinson’s disease: In silico molecular modeling and in vitro ex vivo evaluation. Artif. Cells Nanomed. Biotechnol., 2017, 45(3), 635-648.
[79]
Perez-Lloret, S.; Rey, M.V.; Ratti, P.L.; Rascol, O. Rotigotine transdermal patch for the treatment of Parkinson’s Disease. Fundam. Clin. Pharmacol., 2013, 27(1), 81-95.
[80]
van Wamelen, D.J.V.; Grigorioud, S.; Chaudhuri, K.R.; Odin, P. Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson’s disease. J. Parkinsons Dis., 2018, 8(Suppl. 1), S65-S72.
[81]
Santos, E.U.D.; Duarte, E.B.C.; Miranda, L.M.R.; Asano, A.G.C.; Asano, N.M.J.; Maia, M.M.D.; Souza, P.R.E. Pharmacogenetic profile and the occurrence of visual hallucinations in patients with sporadic Parkinson’s disease. J. Clin. Pharmacol., 2019, 59(7), 1006-1013.
[82]
Mallajosyula, J.K.; Deepinder, K.; Shankar, J.C.; Subramanian, R.; Anand, R.; Nicholls, D.G.; Di Monte, D.A.; Macarthur, H.; Andersen, J.K. MAO-B Elevation in mouse brain astrocytes results in Parkinson’s pathology. PLoS One, 2008, 3(2)e1616
[83]
Liu, B.; Chaonan, L.; Zhang, J.; Liu, Y.; Sun, J.; Cheng, X.; Mao, W.; Ma, Y.; Li, S. Effects of eldepryl on glial cell proliferation and activation in the substantia nigra and striatum in a rat model of Parkinson’s disease. Neurol. Res., 2017, 39(5), 459-467.
[84]
Olanow, C.W.; Rascol, O.; Hauser, R.; Feigin, P.; Jankovic, J.; Lang, A.; Langston, W.; Melamed, E.; Poewe, W.; Stocchi, F.; Tolosa, E. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N. Engl. J. Med., 2009, 361(13), 1268-1278.
[85]
Valldeoriola, F. Consenso de expertos espa˜noles sobre el uso de la safinamida en la enfermedad de Parkinson. Neurologia, 2017.
[86]
Bonifácio, M.J.; Torrão, L.; Loureiro, A.I.; Palma, P.N.; Wright, L.C.; Soares-da-Silva, L. Pharmacological profile of opicapone, a thirdgeneration nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br. J. Pharmacol., 2015, 172(7), 1739-1752.
[87]
Brooks, D.J.; Sagar, H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: A randomised, placebo controlled, double blind, six months study. J. Neurol. Neurosurg. Psychiatry, 2003, 74, 1071-1079.
[88]
Poór, M.; Zrínyi, Z.; Kőszegi, T. Structure related effects of flavonoid aglycones on cell cycle progression of HepG2 cells: Metabolic activation of fisetin and quercetin by catechol-O methyltransferase (COMT). Biomed. Pharmacother., 2016, 83, 998-1005.
[89]
Truong, D.D. Tolcapone: Review of its pharmacology and use as adjunctive therapy in patients with Parkinson’s disease. Clin. Interv. Aging, 2009, 4, 109-113.
[90]
Fabbri, M.; Ferreira, J.J.; Lees, A.; Stocchi, F.; Poewe, W.; Tolosa, E.; Rascol, O. Opicapone for the treatment of Parkinson’s disease: A review of a new licensed medicine. Mov. Disord., 2018, 33(10), 1528-1539.
[91]
Devos, D.; Moreau, C.; Dujardin, K.; Cabantchik, L.; Defebvre, L.; Bordet, R. New pharmacological options for treating advanced Parkinson’s disease. Clin. Ther., 2013, 35(10), 1640-1652.
[92]
Bortolato, M.; Godar, S.C.; Alzghoul, L.; Zhang, J.; Darling, R.D.; Kimberly, L. Simpson, K.L.; Bini, V.; Chen, K.; Wellman, C.L.; Lin, R.C.S.; Shih, J.C. Monoamine oxidase A and A/B knockout mice display autistic-like features. Int. J. Neuropsychopharmacol., 2013, 16(4), 869-888.
[93]
Mrad, M.L.; Zeller, M.; Hernandez, K.J.; Rzaigui, M.; Ben Nasr, C. Bis(adamantan-1-aminium) hydrogen phosphate fumaric acid sesquisolvate. Acta Crystallogr. Sect. E Struct. Rep. Online, 2012, 68(Pt 8), 2531-2532.
[94]
Perez-Lloret, S.; Rascol, O. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J. Neural Transm. (Vienna), 2018, 125(8), 1237-1250.
[95]
Kostelnik, A.; Cegan, A.; Pohanka, M. Anti-Parkinson drug biperiden inhibits enzyme acetylcholinesterase. BioMed Res. Int., 2017, 2017, 1-5.
[96]
Downs, A.M.; Fan, X.; Donsante, C.; Jinnah, H.A.; Hess, E.J. Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia. Neurobiol. Dis., 2019, 125, 115-122.
,
Elias C. Padilha
Download PDF Flyer